Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04671459Phase 2Unknown

TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine

Role: lead

NCT04790097Not ApplicableCompleted

FET-PET Directed Simultaneous In-field Boost for Primary GBM

Role: lead

NCT04814238Unknown

Minimally Invasive Aortic Root and Aorta surGery rEgistry

Role: collaborator

NCT01535209Phase 3Unknown

Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection

Role: collaborator

All 4 trials loaded